|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.54 SEK | -2.71% |
|
+0.12% | +6.99% |
| Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
| Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
Orexo AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was SEK 638.8 million compared to SEK 624.3 million a year ago. Net loss was SEK 128.3 million compared to SEK 177.6 million a year ago.
Basic loss per share from continuing operations was SEK 3.73 compared to SEK 5.17 a year ago. Diluted loss per share from continuing operations was SEK 3.73 compared to SEK 5.17 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +6.99% | 51.97M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
OREXO AB 
